What is Persist AI?
Persist AI is a pioneering technology firm focused on the intersection of artificial intelligence and pharmaceutical manufacturing. The company specializes in AI-driven robotics designed to streamline formulation development and Chemistry, Manufacturing, and Controls (CMC) processes. By integrating predictive AI models with high-throughput automated systems, Persist AI enables pharmaceutical organizations to significantly reduce the time and capital expenditure required to bring novel therapeutics to market.
The company's platform is modality-agnostic, allowing it to support a diverse range of drug development programs. Having graduated from the Y Combinator accelerator in 2023, Persist AI has rapidly established itself as a key player in the life sciences ecosystem, bridging the gap between computational research and physical laboratory execution. Its market position is defined by its ability to solve fundamental bottlenecks in drug discovery, making it an essential partner for firms seeking to optimize their pipeline efficiency.
How much funding has Persist AI raised?
Persist AI has raised a total of $16M across 2 funding rounds:
Other Financing Round
$4M
Series A
$12M
Other Financing Round (2023): $4M with participation from Y Combinator, Innospark Ventures, Pioneer Fund, Fellows Fund, and 2048 Ventures
Series A (2025): $12M led by Good AI Capital, Asymmetry Ventures, Purdue DIAL Ventures, SignalFire, Innospark Ventures, Spero Ventures, Global Brain, Cartography Capital, Y Combinator, MBX Capital, Eli Lilly, and 2048 Ventures
Key Investors in Persist AI
Y Combinator
A premier startup accelerator and investment fund that provides seed capital and operational resources to high-growth technology companies.
Innospark Ventures
A Boston-based early-stage venture fund specializing in the AI-powered economy, with a focus on healthcare, life sciences, and B2B enterprise sectors.
2048 Ventures
A thesis-driven early-stage firm that invests in visionary founders building future technologies across Vertical AI, Deep Tech, and Bio sectors.
What's next for Persist AI?
With this major enterprise-level funding, Persist AI is poised to expand its operational footprint and enhance its robotic infrastructure. The strategic roadmap likely includes scaling its team of engineers and scientists, as well as deepening its partnerships with global biopharmaceutical entities. As the firm continues to refine its predictive models, the focus will shift toward broader commercial adoption and the integration of its technology into larger-scale manufacturing workflows.
The backing from a diverse syndicate of investors—ranging from specialized AI-focused venture firms to industry-specific strategic partners—provides Persist AI with the necessary operational support to navigate the complexities of the healthcare sector. Moving forward, the company is expected to prioritize the deployment of its systems across new therapeutic modalities, aiming to set a new industry standard for speed and precision in drug formulation.
